Vera Therapeutics Inc Cl A (VERA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -62,091 | -28,383 | -95,990 | -70,335 | -50,231 |
| Depreciation Amortization | -4,063 | -1,469 | -4,086 | -2,919 | -1,477 |
| Accounts payable and accrued liabilities | -6,454 | -5,909 | -873 | 309 | 1,289 |
| Other Working Capital | -2,475 | -8,619 | -5,822 | -3,747 | 1,152 |
| Other Operating Activity | 16,471 | 10,550 | 14,590 | 9,655 | 5,203 |
| Operating Cash Flow | $-58,612 | $-33,830 | $-92,181 | $-67,037 | $-44,064 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -89 | N/A | -63 | N/A | N/A |
| Purchase Of Investment | -336,055 | -254,967 | -224,930 | -171,730 | -143,058 |
| Sale Of Investment | 94,181 | 35,681 | 185,562 | 113,743 | 68,843 |
| Investing Cash Flow | $-241,963 | $-219,286 | $-39,431 | $-57,987 | $-74,215 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 24,741 | N/A | N/A |
| Common Stock Issued | 297,850 | 294,411 | 116,056 | 115,969 | 115,672 |
| Other Financing Activity | -17,871 | -17,871 | -7,256 | -7,256 | -7,256 |
| Financing Cash Flow | $279,979 | $276,540 | $133,541 | $108,713 | $108,416 |
| Beginning Cash Position | 45,681 | 45,681 | 43,752 | 43,752 | 43,752 |
| End Cash Position | 25,085 | 69,105 | 45,681 | 27,441 | 33,889 |
| Net Cash Flow | $-20,596 | $23,424 | $1,929 | $-16,311 | $-9,863 |
| Free Cash Flow | |||||
| Operating Cash Flow | -58,612 | -33,830 | -92,181 | -67,037 | -44,064 |
| Capital Expenditure | -89 | N/A | -63 | N/A | N/A |
| Free Cash Flow | -58,701 | -33,830 | -92,244 | -67,037 | -44,064 |